Sign Up Now to Download a Free Research Report on ONCY
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Oncolytics Biotech, Inc.
Oncolytics Biotech shares traded in the range of $2.64 to $3.06 Wednesday. The company announced that its metastatic melanoma treatment met its primary endpoint in a recent U.S. Phase 2 clinical trial. Shares of Oncolytics have fallen approximately 31 percent year-to-date.
Going forward ... (see research report)
Subscribe to News Feeds